首页> 美国卫生研究院文献>Journal of Clinical Oncology >Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

【2h】

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

机译：NETLu-1 III期临床试验中用177Lu-Dotatate治疗进行性中肠神经内分泌肿瘤患者的健康相关生活质量

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeNeuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of ¹⁷⁷Lu-Dotatate treatment on time to deterioration in health-related QoL.

机译：目的神经内分泌肿瘤（NET）的进展与生活质量（QoL）的降低有关。我们评估了^{177 Lu-Dotatate治疗对健康相关QoL恶化时间的影响。}

著录项

期刊名称 Journal of Clinical Oncology
作者
Jonathan Strosberg; Edward Wolin; Beth Chasen; Matthew Kulke; David Bushnell; Martyn Caplin; Richard P. Baum; Pamela Kunz; Timothy Hobday; Andrew Hendifar; Kjell Oberg; Maribel Lopera Sierra; Thomas Thevenet; Ines Margalet; Philippe Ruszniewski; Eric Krenning;
展开▼
作者单位

展开▼
年(卷),期 -1(36),25
年度 -1
页码 2578–2584
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-177-Dotatate in the Phase III NETTER-1 Trial [J] . Strosberg Jonathan, Wolin Edward, Chasen Beth, Journal of Clinical Oncology . 2018,第25期

机译：在III期VETTER-1试验中使用Lu-177-177-乳腺癌治疗的患者健康相关的生活质量患者
2. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate: Efficacy, Safety, QoL Results, and Subgroup Analysis [J] . Strosberg Jonathan, Wolin Edward, Chasen Beth, Pancreas . 2017,第3期

机译：患有177次致乳腺酸盐治疗的中肠神经内分泌肿瘤的Netter-1期III：疗效，安全性，QOL结果和亚组分析
3. QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors [J] . Strosberg Jonathan, Wolin Edward, Chasen Beth, Pancreas . 2018,第3期

机译：QOL改善患者患者患者患者患者中脑内神经内分泌肿瘤
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. Relationship between Quality of Life for Patients with Neuroendocrine Tumors and Novel Biomarkers [D] . Ford-Scheimer, Stephanie L. 2017

机译：神经内分泌肿瘤和新型生物标志物患者生活质量的关系
6. OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101) [O] . M. J. B. Taphoorn, A. Bottomley, C. Coens, 2016

机译：OS5.2贝伐珠单抗联合洛莫司汀与仅洛莫司汀治疗的进行性胶质母细胞瘤患者的健康相关生活质量（HRQoL）（III期EORTC研究26101）
7. Health-related quality of life in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumors with everolimus vs. placebo in the phase 3, randomized, RADIANT-4 trial [O] . Pavel, Marianne E, Singh, Simron, Strosberg, Jonathan, 2027

机译：与随机分组RaDIaNT-4试验相比，依那莫司与安慰剂相比，晚期，非功能性，分化良好的胃肠道或肺神经内分泌肿瘤患者的健康相关生活质量

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

摘要

著录项

相似文献

相关主题

期刊订阅